---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-000232"
form_type: "8-K"
ticker: "PULM"
cik: "0001574235"
company_name: "Pulmatrix, Inc."
filed_at: "2023-01-04T23:59:59+00:00"
generated_at: "2026-06-20T20:18:52.369547+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pulmatrix reports positive Phase 1 results for inhaled migraine drug PUR3100; Tmax 5 min, fewer GI side effects

## Summary
- PUR3100 was safe and well-tolerated; no emesis in any dose group; lower nausea incidence vs IV DHE.
- Peak plasma concentration (Cmax) reached targeted therapeutic range at all three doses; Tmax of 5 minutes.
- Phase 2 dose selection underway; FDA meeting requested in January 2023.
- Study enrolled 26 healthy subjects in double-dummy, double-blinded design comparing inhaled PUR3100 vs IV DHE.

## SEC filing metadata
- accession: 0001493152-23-000232
- form_type: 8-K
- ticker: PULM
- cik: 0001574235
- company_name: Pulmatrix, Inc.
- filed_at: 2023-01-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574235/000149315223000232/0001493152-23-000232-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574235/000149315223000232/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-000232
- JSON: https://secwatch.observer/filing/0001493152-23-000232.json
- Plain text: https://secwatch.observer/filing/0001493152-23-000232.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.